Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19
- 1 April 2021
- journal article
- case report
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 35 (4) , 1149-1153
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19New England Journal of Medicine, 2020
- Incidence of thrombotic complications in critically ill ICU patients with COVID-19Thrombosis Research, 2020
- Evaluation of Bivalirudin As an Alternative to Heparin for Systemic Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation*Pediatric Critical Care Medicine, 2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Anticoagulation Therapy in ChildrenSeminars in Thrombosis and Hemostasis, 2017
- Bivalirudin Versus Heparin as an Anticoagulant During Extracorporeal Membrane Oxygenation: A Case-Control StudyJournal of Cardiothoracic and Vascular Anesthesia, 2013
- Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenationCritical Care, 2011
- Thrombin During Cardiopulmonary BypassThe Annals of Thoracic Surgery, 2006
- Bivalent direct thrombin inhibitors: hirudin and bivalirudinBest Practice & Research Clinical Haematology, 2004